It is increasingly recognized that the immune system plays a pivotal role in a range of acute and chronic diseases, including infection, cancer and autoimmune disorders. Therapeutic modulation of the immune system – using the body’s own defenses to more effectively fight disease – has become an important emerging area of pharmaceutical research and development, revolutionizing the treatment of many life-threatening and debilitating diseases.
Over the past 20 years, Immuno Research Inc. (formerly Biothera Inc.) has established world-leading expertise in the biology and therapeutic application of a range of novel, proprietary, immune modulators with a unique mechanism of action. These compounds, beta-1,3-1,6 glucans, have characteristics that make them ideal for development as highly differentiated therapeutic immune modulators.
Immuno Research has an extensive intellectual property portfolio and has established preclinical, clinical and commercial proof of concept for its beta-glucan technology platform in a range of applications, including cancer immunotherapy drug development and immune support ingredients for foods, beverages and supplements. Immuno Research is a technology incubator that is developing novel beta glucans for a wide range of non-oncology pharmaceutical applications. Led by an experienced management team, we are building a range of collaborations with globally recognized academic partners in order to continue discovery of new beta-glucans and applications. Once preclinical proof of concept is established, we will seek appropriate partners to advance and commercialize the technology.